BPC-157 Tablets: Sublingual and Oral Tablet Forms

BPC-157 tablets serve as another oral delivery method of the compound, however, they are produced in a different way than capsules, potentially affecting how the peptide is delivered. Tablets are a product of high-pressure compression of the powder while capsules are solid shells filled with the powder that dissolves once swallowed. The difference is significant for peptides as the process of compressing the powder generates heat and mechanical force so damaging delicate molecules. Existing literature on BPC-157 tablets is scarce with almost all research on oral BPC-157 involving the compound dissolved in water.

Tablets vs Capsules: How They Are Made

Tablet Manufacturing

Tableting is done by compressing a mixture of active ingredient and excipients (binders, fillers, lubricants, disintegrants) in a tablet press under a pressure up to several kilonewtons, during which heat is generated. When it comes to low molecular weight drugs like aspirin or ibuprofen, this is not an issue but with peptides it is important, given that they could denature with mechanical and thermal stress. Another important aspect of tablet preparation is how tablet ingredients interact with each other, leading to variations in tablet disintegration speed and hence drug release.

Capsule Manufacturing

Capsules consist of a two-piece shell, either gelatin or hydroxypropyl methylcellulose (HPMC), filled with powder or granules. No compression step is involved. The peptide powder is blended with excipients and poured into the capsule body, then the cap is sealed. This gentler process exposes the peptide to less mechanical and thermal stress. Dissolution depends on the shell material: gelatin dissolves in stomach acid within 5 to 10 minutes, while HPMC capsules may take slightly longer. Enteric-coated capsules resist stomach acid and dissolve at the higher pH of the small intestine.

Compression Heat and Peptide Integrity

Why This Matters for BPC-157

Peptide bonds are susceptible to thermal degradation. While BPC-157 demonstrates unusual acid stability, its resistance to heat and mechanical force has not been characterized in published literature. Tablet compression can produce surface temperatures of 40 to 60 degrees Celsius at the compression point, depending on speed, force and formulation. Most proteins and peptides begin to lose structural integrity above 40 to 50 degrees Celsius. If BPC-157 partially degrades during tablet compression, the final product may contain a mixture of intact peptide and inactive fragments.

No Published Stability Data for Tablets

To the best of our knowledge, there is no research that has investigated the stability of BPC-157 in tablets after compression. The 2025 formulation review addressed the difficulties related to oral peptide delivery, but it failed to assess the degradation of BPC-157 in tablets. Consequently, it remains unclear that any given BPC-157 tablet offers the same quantity of the active peptide as a capsule with the same dose on the label.

Sublingual Delivery Claims

What Sublingual Means

Sublingual tablets are formulated to melt beneath the tongue, promoting the absorption of the peptide in the bloodstream via the fragile mucosal tissues present. As a result, this method ensures that the peptide circumvents any possible destruction by gastric juice and any changes resulting from first-pass metabolism in the liver. In this regard, many products containing BPC-157 are available as sublingual tablets.

Published Evidence

There has been no published research that determines the absorption of BPC-157 through the sublingual mucosa. The molecular weight of BPC-157 (around 1419 daltons) makes it larger than what is typically allowed for drug absorption through the sublingual route. The ideal molecular size for good sublingual absorption generally lies between 500 and 1000 daltons. Very low molecular lipophilic compounds such as nitroglycerin and certain hormones are readily absorbed sublingually, while large hydrophilic peptides do not pass through the sublingual route of administration. It is still unknown whether the structural characteristics of BPC-157 will allow its sublingual absorption at adequate rates.

Products Available

Real Peptides offers BPC-157 in capsule form (100 count, 500 mcg each, $120) with HPLC purity at 99% or higher and lot-specific COA. They also sell a 10 mg lyophilized vial at $43.20 ($4.32/mg). PeptideGod sells BPC-157 as a lyophilized vial at $34.95 with no disclosed milligram content and no published COA. Neither Real Peptides nor PeptideGod currently markets a BPC-157 tablet product. Tablet products from other manufacturers exist but are outside the scope of this review.

Head-to-Head: Tablets vs Capsules for BPC-157

Which Format Is Better?

No validation study has been published for either form of BPC-157 in a clinical setting. The animal studies that showed activity of oral BPC-157 used the peptide dissolved in water, rather than in tablets or capsules. Theoretically, capsules are less likely to degrade. In practice, however, there have been no stability or bioequivalence studies for either formulation of BPC-157.

For buyers who specifically want oral BPC-157, capsules from a vendor that provides HPLC-verified COA documentation represent the lower-risk option between the two solid formats, based on the manufacturing process alone. Tablets, particularly sublingual tablets, introduce additional variables with no published data to resolve them. For a broader comparison of oral versus injectable routes, see our capsules vs injection page. For the underlying absorption science, see the oral bioavailability guide.